Application of diagnostic criteria for optic neuritis
- PMID: 37059501
- DOI: 10.1016/S1474-4422(23)00112-6
Application of diagnostic criteria for optic neuritis
Conflict of interest statement
AB declares no competing interests. SG reports honoraria for lectures and travel grants from Alnylam Pharmaceuticals and Merck; and his research is supported by the Deutsche Forschungsgemeinschaft, Else Kröner Fresenius Foundation, Hannover Biomedical Research School, Alnylam Pharmaceuticals, and CSL Behring. KFJ reports travel grants from Merck and Novartis; and his research is supported by the Else Kröner Fresenius Foundation. SGM reports honoraria for lectures and travel grants from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, Teva, and Destitin; and his research is supported by the German Ministry for Education and Research, Bundesinstitut für Risikobewertung, Deutsche Forschungsgemeinschaft, Else Kröner Fresenius Foundation, Gemeinsamer Bundesausschuss, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies Muenster, German Foundation Neurology, Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. TS reports honoraria for lectures and travel grants from Alexion, Alnylam Pharmaceuticals, Argenx, Bayer Vital, Biogen, Celgene, Centogene, CSL Behring, Euroimmun, Janssen, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Siemens, Sobi, and Teva; and his research is supported by the German Ministry for Education and Research, Bristol-Myers Squibb Foundation for Immuno-Oncology, Claudia von Schilling Foundation for Breast Cancer Research, Else Kröner Fresenius Foundation, Hannover Biomedical Research School, Alnylam Pharmaceuticals, CSL Behring, Novartis, Sanofi Genzyme, and VHV Foundation.
Comment in
-
Application of diagnostic criteria for optic neuritis - Authors' reply.Lancet Neurol. 2023 May;22(5):376-377. doi: 10.1016/S1474-4422(23)00110-2. Lancet Neurol. 2023. PMID: 37059502 No abstract available.
Comment on
-
Diagnosis and classification of optic neuritis.Lancet Neurol. 2022 Dec;21(12):1120-1134. doi: 10.1016/S1474-4422(22)00200-9. Epub 2022 Sep 27. Lancet Neurol. 2022. PMID: 36179757 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical